Q2 2022 HTG Molecular Diagnostics Inc Earnings Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the HTG Molecular Diagnostics, Inc. Second Quarter 2022 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Andrew Eriksen of LifeSci Advisors. Please go ahead.
Before we begin the call today, let me remind you that the company's remarks include forward-looking statements within the meaning of the federal securities laws, including statements regarding our expected revenue build and momentum in 2022, our expectations regarding profiling revenue in future periods, our expectation that customers may use our HTP and whole transcriptome mRNA panel for their studies as a result of the harmonized sample preparation protocol, the importance of the company's HTG transcriptome panel, statements related to the company's HTG Therapeutics and Drug Discovery business, the impacts of recent hires, our planned white paper for a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |